Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Cash Flow: 2012-2024

Historic Net Cash Flow for Rocket Pharmaceuticals (RCKT) over the last 13 years, with Dec 2024 value amounting to $107.7 million.

  • Rocket Pharmaceuticals' Net Cash Flow rose 59.78% to $43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 106.47%. This contributed to the annual value of $107.7 million for FY2024, which is 227.36% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Net Cash Flow stood at $107.7 million for FY2024, which was up 227.36% from -$84.6 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Net Cash Flow peaked at $111.8 million during FY2020, and registered a low of -$92.2 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$84.6 million (2023), whereas its average is -$23.0 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Net Cash Flow tumbled by 157.83% in 2021, and later spiked by 227.36% in 2024.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Net Cash Flow stood at $111.8 million in 2020, then crashed by 157.83% to -$64.6 million in 2021, then tumbled by 42.63% to -$92.2 million in 2022, then increased by 8.24% to -$84.6 million in 2023, then surged by 227.36% to $107.7 million in 2024.